These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 34068664)

  • 1. Clinical Indications for Treatment with Multi-Kinase Inhibitors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer.
    Fukuda N; Takahashi S
    Cancers (Basel); 2021 May; 13(9):. PubMed ID: 34068664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation.
    Fleeman N; Houten R; Bagust A; Richardson M; Beale S; Boland A; Dundar Y; Greenhalgh J; Hounsome J; Duarte R; Shenoy A
    Health Technol Assess; 2020 Jan; 24(2):1-180. PubMed ID: 31931920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.
    Kiyota N; Robinson B; Shah M; Hoff AO; Taylor MH; Li D; Dutcus CE; Lee EK; Kim SB; Tahara M
    Thyroid; 2017 Sep; 27(9):1135-1141. PubMed ID: 28665259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
    Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
    Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictors of Response and Survival to Multikinase Inhibitors in Radioiodine Resistant Differentiated Thyroid Cancer.
    Feola T; Cozzolino A; Centello R; Pandozzi C; Tarsitano MG; Giannetta E
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.
    Ito Y; Onoda N; Kudo T; Masuoka H; Higashiyama T; Kihara M; Miya A; Miyauchi A
    In Vivo; 2021; 35(2):1057-1064. PubMed ID: 33622902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The experience of an Endocrinology Division on the use of tyrosine multikinase inhibitor therapy in patients with radioiodine-resistant differentiated thyroid cancer.
    Jerkovich F; García Falcone MG; Pitoia F
    Endocrine; 2019 Jun; 64(3):632-638. PubMed ID: 30820748
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
    Wilson L; Huang W; Chen L; Ting J; Cao V
    Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Real-World Observation of Patients Treated with Sorafenib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Impact of Lenvatinib Salvage Treatment: A Korean Multicenter Study.
    Oh HS; Shin DY; Kim M; Park SY; Kim TH; Kim BH; Kim EY; Kim WB; Chung JH; Shong YK; Lim DJ; Kim WG
    Thyroid; 2019 Dec; 29(12):1804-1810. PubMed ID: 31592739
    [No Abstract]   [Full Text] [Related]  

  • 10. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients.
    Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Masaki C; Akaishi J; Hames KY; Tomoda C; Ogimi Y; Ito K
    Endocr J; 2018 Mar; 65(3):299-306. PubMed ID: 29269689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.
    Tumino D; Frasca F; Newbold K
    Front Endocrinol (Lausanne); 2017; 8():312. PubMed ID: 29209273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective use of sorafenib in the treatment of thyroid cancer.
    Pitoia F; Jerkovich F
    Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety of Tyrosine Kinase Inhibitors in Patients With Differentiated Thyroid Cancer: Real-World Use of Lenvatinib and Sorafenib in Korea.
    Kim SY; Kim SM; Chang H; Kim BW; Lee YS; Chang HS; Park CS
    Front Endocrinol (Lausanne); 2019; 10():384. PubMed ID: 31244783
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
    Song E; Kim M; Kim EY; Kim BH; Shin DY; Kang HC; Ahn BC; Kim WB; Shong YK; Jeon MJ; Lim DJ
    Thyroid; 2020 May; 30(5):732-738. PubMed ID: 31910091
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects and Role of Multikinase Inhibitors in Thyroid Cancer.
    Laursen R; Wehland M; Kopp S; Pietsch J; Infanger M; Grosse J; Grimm D
    Curr Pharm Des; 2016; 22(39):5915-5926. PubMed ID: 27306093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
    Jing R; Wu N; Wu Y; Zhang Q; Liang Q; Huang P; Yi S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2658-2672. PubMed ID: 38970485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of multikinase inhibitors/lenvatinib concomitant with antiresorptive therapy for bone metastases from radioiodine-resistant differentiated thyroid cancer.
    Navarro-Gonzalez E
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):54-58. PubMed ID: 35785524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of lenvatinib in treating thyroid cancer.
    Krajewska J; Kukulska A; Jarzab B
    Expert Opin Pharmacother; 2016 Aug; 17(12):1683-91. PubMed ID: 27398740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.